Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Wake Forest University Health Sciences
Pfizer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Kelonia Therapeutics, Inc.
Emory University
Shenzhen University General Hospital
Astex Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
Celularity Incorporated
University of California, San Francisco
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gilead Sciences
Merck Sharp & Dohme LLC
Baylor College of Medicine
M.D. Anderson Cancer Center
Baylor College of Medicine
Seagen Inc.
Seagen Inc.
AVEO Pharmaceuticals, Inc.
Washington University School of Medicine